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Abstract 
Dietary restriction (DR) represents one of the most reproducible interventions to extend lifespan and 
improve health outcomes in a wide range of species, but substantial variability in DR response has 
been observed, both between and within species. The mechanisms underlying this variation in effect 
are still not well characterised. Splicing regulatory factors have been implicated in the pathways linked 
with DR-induced longevity in C. elegans and are associated with lifespan itself in mice and humans.  
We used qRT-PCR to measure the expression levels of a panel of 20 age- and lifespan-associated 
splicing regulatory factors in brain, heart and kidney derived from three recombinant inbred strains of 
mice with variable lifespan responses to short-term (2 months) or long-term (10 months) 40% DR to 
determine their relationship to DR-induced longevity. 
We identified 3 patterns of association; i) splicing factors associated with DR alone, ii) splicing factors 
associated with strain alone or iii) splicing factors associated with both DR and strain. Tissue specific 
variation was noted in response to short term or long-term DR, with the majority of effects noted in 
brain following long term DR in the positive responder strain TejJ89. Association in heart and kidney 
were less evident, and occurred following short term DR. 
Splicing factors associated with both DR and strain may be mechanistically involved in strain-specific 
differences in response to DR. We provide here evidence concordant with a role for some splicing 
factors in the lifespan modulatory effects of DR across different mouse strains and in different tissues. 
  
1. Introduction 
Since the lifespan extension effects of dietary restriction (DR) were first reported in the early 1900s 
(McCay and others 1928; Osborne and others 1917), intensive effort has focused on characterisation 
of the underlying mechanism(s) in model organisms (Gems and Partridge 2013; Mair and Dillin 2008; 
Speakman and Mitchell 2011). Several studies have shown the beneficial effects of DR in terms of 
extended lifespan to be conserved across many species ranging from single-celled organisms to non-
human primates (Austad 1989; Kealy and others 2002; Masoro 2005; Mattison and others 2017). To 
date no lifespan data are available in humans, although there are many opinions as to the potential for 
DR to affect human lifespan (Cava and Fontana 2013; Ingram and others 2006; Phelan and Rose 
2005; Speakman and Hambly 2007; Speakman and Mitchell 2011). Notwithstanding the reported 
effects on lifespan, there remains clear evidence that DR results in multiple health benefits in many 
organisms including humans (Cava and Fontana 2013; Heilbronn and others 2006; Larson-Meyer and 
others 2006; Smith and others 2010). These benefits could contribute to extended ‘health span’ (the 
period of life spent free from age-related chronic diseases) in ageing human populations, which is 
arguably far more relevant from a public health perspective than increasing lifespan alone. However, 
the exact nature of the mechanism(s) which lead to such benefits remains the subject of discussion. 
There is therefore a need to elucidate the pathways underlying the actions of DR in order to better 
understand how it could potentially be used to extend ‘health span’ in human populations. 
When discussing DR as a potential intervention, it must be recognised that the universality of the 
beneficial effects is far from clear cut. In animal models, lifespan extension results vary with the 
experimental methodology used; animal husbandry conditions, level of DR imposed, age at initiation 
of DR and method of introduction of DR may all influence the amount of extension reported (Ingram 
and de Cabo 2017; Selman and Swindell 2018; Vaughan and others 2017). Genetics is clearly also an 
important factor to be considered, especially given that studies conducted across different species 
show highly variable effects, with several reports showing dietary restriction to have no effect, or even 
a negative effect on lifespan (Mockett and others 2006; Selman and Swindell 2018; Speakman and 
Mitchell 2011). However, such disparity is not limited to cross-species differences; two studies from 
2010 (Liao and others 2010; Rikke and others 2010) tested a large number of ILSXISS recombinant 
inbred mouse strains and reported wide variability in lifespan response to 40% DR, both lifespan 
extension and lifespan reduction were observed in similar numbers of strains in each of these 
experiments. It is currently unclear as to what caused the variation in response to DR, although a 
number of reasons have been suggested (Selman and Swindell 2018). However, the simple fact that 
such variation exists presents valuable opportunities to study the molecular mechanisms involved in 
differential lifespan response to dietary restriction. 
One molecular mechanism with potential to play a role in the DR response is alternative mRNA splicing; 
components of the machinery that regulates this process have previously been implicated in DR in 
C.elegans (Heintz and others 2017) . Alternative splicing is known to be a contributor to cellular 
plasticity and is a key element of the homeostatic stress response, both of which are important factors 
in the ageing process (Kelemen and others 2013; Kourtis and Tavernarakis 2011). Dysregulated 
splicing is also a major feature of age-related diseases including Alzheimer’s disease, Parkinson’s 
disease and several tumour types (Danan-Gotthold and others 2015; Lisowiec and others 2015; 
Scuderi and others 2014). Regulation of alternative splicing events is complex and multifactorial, 
however trans-acting splicing factors are necessary to determine the outcome of any particular splicing 
event (Smith and Valcarcel 2000). The Serine Arginine-rich (SR) family of splicing factors and the 
heterogeneous nuclear ribonucleoprotein (HNRNP) family of splicing factors usually, but not 
exclusively, have stimulatory and inhibitory roles respectively in the determination of splice site usage 
(Cartegni and others 2002). We have previously shown that alternative splicing and splicing factor 
expression are deregulated during normal human ageing (Harries and others 2011) and that splicing 
factor expression levels are associated with lifespan in mice and humans (Lee and others 2016). We 
have also demonstrated changes in splicing factor expression in senescent cells from multiple human 
tissue types in vitro (Holly and others 2013; Latorre and others 2018b) and recently we reported the 
reversal of several senescent cell phenotypes through moderation of splicing factor expression levels 
using resveratrol analogues, hydrogen sulfide donors or inhibition of the ERK or AKT signalling 
pathways in cultured human cells (Latorre and others 2017; Latorre and others 2018a; Latorre and 
others 2018c). 
Given the emerging importance of splicing factors in the ageing phenotype and links to longevity, we 
hypothesised that their expression may be altered under DR conditions, and may present some insight 
into the role of alternative splicing in the effects of DR. To explore this, we measured splicing factor 
transcript expression levels in three recombinant ILSXISS mouse strains with differential responses to 
short term or long term 40% DR. We identified striking tissue specificity in expression profiles. The 
expression of some splicing factors was associated with exposure to either short-term or long-term DR, 
or both, but demonstrated no associations with strain. Others demonstrated strain specific responses 
but were unrelated to DR status. Some splicing factors however demonstrated interactions between 
both strain and DR, and may underlie the observed strain specificity in DR response. 
 
2. Methods 
2.1. ILSXISS Mice 
The mouse strains used in the present study have been extensively described elsewhere (Bennett and 
others 2002; Liao and others 2010; Mulvey and others 2017; Rikke and others 2010; Williams and 
others 2004). In brief, the ILSXISS recombinant inbred (RI) mouse strains were originally derived from 
a cross between inbred long sleep (ILS) and inbred short sleep (ISS) mice. These two strains were 
developed from an original eight-way cross using heterogeneous stock; A, AKR, BALB/c, C3H/2, 
C57BL, DBA/2, IsBi and RIII, the offspring of which were subsequently bred for differential ethanol 
sensitivity, giving the long and short sleep models. Over 20 successive generations of inbreeding of 
these progenitor strains (ILS X ISS) resulted in more than 75 ILSXISS RI lines, each genetically distinct 
from each other (Liao and others 2010). These lines have previously been shown to have variable 
lifespan responses to DR, making them ideal for exploration of the mechanisms underlying DR-induced 
lifespan extension (Liao and others 2010; Rikke and others 2010).  
Mice from three of these strains were chosen for use in the present study, on the basis of replicable 
responses to 40% DR across two previous independent studies with no significant strain-specific 
differences in median lifespan under AL conditions (Liao and others 2010; Rikke and others 2010). 
Only female mice were used in the present study for consistency since one previous study (Rikke and 
others 2010) did not include male mice. Lifespan measurements from the Liao study (Liao and others 
2010) therefore could not be corroborated for both sexes. Mice were maintained in groups of 4 post-
weaning in shoebox cages (48 cm × 15 cm × 13 cm), with AL access to water and standard chow 
(CRM(P), Research Diets Services, LBS Biotech, UK; Atwater Fuel Energy-protein 22%, carbohydrate 
69%, fat 9%) and maintained on a 12L/12D cycle (lights on 0700–1900h) at 22 ± 2 °C.  
One of the strains chosen showed an extension of lifespan under life-long 40% DR (TejJ89), one 
showed a lifespan reduction response to 40% DR (TejJ114) and one exhibited no response to 40% 
DR (TejJ48) relative to strain-specific ad libitum fed controls. There is some debate as to whether these 
strain responses truly reflect each strain’s true potential for lifespan extension or simply that a 40% DR 
regime is sub-optimal in the cases of TejJ48 and TejJ114 (Selman and Swindell 2018). However for 
purposes of clarity, the strains will be referred to as positive-, negative- and non-responder strains 
since these are the responses that have previously been reported under 40% DR (Liao and others 
2010; Mulvey and others 2017; Rikke and others 2010). Mice were introduced to DR in a graded 
fashion; at 10 weeks of age mice were exposed to 10% DR (90% of AL feeding), at 11 weeks this was 
increased to 20% DR, and from 12 weeks of age until the termination of the experiment mice were 
exposed to 40% DR, relative to their appropriate strain-specific AL controls. Mice were given either ad 
libitum (AL) feed or short- (2 months) or long-term (10 months) 40% DR, as previously published 
(Mulvey and others 2017). Brain, heart and kidney tissue samples were collected as part of a previous 
study, therefore full details of animal husbandry conditions, DR protocols and treatment of dissected 
tissues have all been previously described in Mulvey et al (Mulvey and others 2017). All experiments 
were carried out under a licence from the UK Home Office (Project Licence 60/4504) and followed the 
“principles of laboratory animal care” (NIH Publication No.86-23, revised 1985). 
 
2.2. Splicing factor candidate genes for analysis 
An a priori list of splicing factor candidate genes were chosen based on associations previously seen 
in multiple human aging cohorts and in senescent primary human cell lines (Harries and others 2011; 
Holly and others 2013; Latorre and others 2017; Latorre and others 2018b). Some of the splicing factors 
in this list have also been shown to associate with lifespan in both mice and humans (Lee and others 
2016). The list of genes included the negative regulatory splicing factors Hnrnpa0, Hnrnpa1, 
Hnrnpa2b1, Hnrnpd, Hnrnph3, Hnrnpk, Hnrnpm, Hnrnpul2, the positive regulatory splicing enhancers 
Pnisr, Srsf1, Srsf2, Srsf3, Srsf6, Tra2b and the core components of the spliceosome Sf1 and Sf3b1. 
Expression assays were obtained in single-tube TaqMan® Assays-on-Demand™ format 
(ThermoFisher, Waltham, MA, USA). Assay Identifiers are given in Supplementary Table S1. 
 
2.3. RNA extraction 
Snap-frozen tissues were first treated with RNAlater™-ICE Frozen Tissue Transition Solution 
(ThermoFisher, Waltham, MA, USA) according to the manufacturer’s instructions, in order to allow 
handling of the tissue without RNA degradation occurring due to thawing of sample. Tissue sections 
were then placed in 1 mL TRI Reagent® Solution (ThermoFisher, Waltham, MA, USA) supplemented 
with the addition of 10mM MgCl2 to aid recovery of microRNAs (Kim and others 2012). Samples were 
then completely homogenized in a bead mill (Retsch Technology GmbH, Haan, Germany) at a 
frequency of 30 cycles per second for 15 mins. Phase separation was carried out using chloroform. 
Total RNA was precipitated from the aqueous phase by means of an overnight incubation at -20°C with 
isopropanol. 1.2µl Invitrogen™ GlycoBlue™ Coprecipitant (ThermoFisher, Waltham, MA, USA) was 
added prior to incubation to aid pellet recovery. RNA pellets were then ethanol-washed twice and re-
suspended in 1X TE buffer, pH8.0. RNA quality and concentration were assessed by NanoDrop 
spectrophotometry (NanoDrop, Wilmington, DE, USA).  
 
2.4. Reverse transcription 
500ng of total RNA was reverse transcribed using EvoScript Universal cDNA Master kit (Roche 
LifeScience, Burgess Hill, West Sussex, UK) in 20µl reactions, according to the manufacturer’s 
instructions except for a change to the extension phase of the reaction: a step of 30 minutes at 65°C 
was used instead of 15 minutes at 65°C. Resulting cDNA was then diluted to a final volume of 80µl 
with dH2O to ensure sufficient volume for all subsequent qRT-PCR reactions. 
 
2.5. Quantitative real-time PCR 
1.0µl cDNA (reverse transcribed as indicated above) was added to a 5µl qRT-PCR reaction including 
2.5µl TaqMan® Universal Master Mix II, no UNG (ThermoFisher, Waltham, MA, USA) and 0.125µl 
TaqMan® Assays-on-Demand™ probe and primer mix (corresponding to 450nM each primer and 
125nM probe). Reactions were run in triplicate on 384-well plates using the QuantStudio 6 Flex Real-
Time PCR System (ThermoFisher, Waltham, MA, USA). Amplification conditions were a single cycle 
of 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. As this 
study consisted of a collection of 288 samples, three separate plates were required to run all samples 
with each Taqman® assay. To mitigate the effects of plate-to-plate variation, two approaches were 
used. Firstly, samples were randomised before being assigned to a plate such that any given plate did 
not contain all the samples from one strain, tissue or DR condition. Secondly, internal calibrator 
samples were used: 6 samples were chosen at random from the collection and separate to the main 
workflow, each sample was reverse-transcribed 3 times and diluted as described above. The 3 
resulting cDNA samples were then pooled for each sample, mixed thoroughly and then added as extra 
samples to each plate. These internal calibrator samples were then used in the downstream analysis 
to normalise across plates. 
 
2.6. Data preparation 
EDS files were uploaded to the ThermoFisher Cloud (ThermoFisher, Waltham, MA, USA) and analysed 
using the Relative Quantification qPCR App within the software 
(https://www.thermofisher.com/uk/en/home/cloud.html). This platform was used to manually set 
Baseline and Threshold for each assay (see Supplementary Table S1 for values) and to ensure there 
were no apparent outliers before further analysis. One sample was excluded from the TejJ89 dataset 
at this stage as expression data was missing for >50% of all genes measured. Output was imported 
into Excel (Microsoft, Redmond, WA, USA) and the CT values used for analysis using the comparative 
CT method. First, raw CT values were corrected using the internal calibrator samples from each of the 
three plates. Corrected CT data from all genes measured, endogenous controls, calculated averages 
and geometric means of these controls along with calculated ‘global’ averages and geometric means 
across all genes measured were then uploaded to the RefFinder webtool (Xie and others 2012) to 
establish the most stable gene(s). This returned the ‘global’ geometric mean value across all genes 
measured as the most stable and thus the most appropriate for the ΔCT normalisation step. At this 
point, ΔΔCT expression calculations were performed for each strain separately; expression for each 
transcript was calculated relative to the average expression in the ad-libitum fed animals, for each 
tissue individually and separately for long-term and short-term treatments. Following the ΔΔCT 
normalisation, the fold-changes were calculated using the 2-ΔΔCT method, followed by an additional 
normalisation using the geometric mean expression of the non-responder strain (TejJ48) as a baseline.  
This final normalisation step was intended to account for any minor changes in splicing factor 
expression caused by DR, but presumably unrelated to the lifespan-alteration response seen in the 
positive (TejJ89) and negative (TejJ114) responder strains. The expression profiles of splicing factors 
in the non-responder strain (TejJ48) under DR conditions are shown in Supplementary Figure S1 and 
Supplementary Table S2. As can be seen, there are very few significant alterations in expression levels 
(and none that meet multiple testing criteria), although a certain amount of deviation from zero can be 
seen. These deviations in expression are likely to be brought about through the imposition of a DR 
regime, however owing to the lack of response in this strain it is reasonable to assume that they are 
highly unlikely to be contributory to the responses seen in the other strains. As such, normalisation 
using these minor deviations should merely remove a certain amount of ‘background’ from the positive- 
and negative-responder strain data. As a consequence of this normalisation, the data from TejJ48 were 
effectively set as a zero point against which TejJ89 and TejJ114 were compared, so results for TejJ48 
are presented only in supplementary data. 
Data were log transformed to ensure normal distribution and outlier detection was then performed in 
SPSS (IBM, Armonk, NY, USA). Univariate outliers were identified using standardised z-scores, with 
any individual measures for each gene falling outside the cut-off (set at 3 standard deviations from the 
mean) being discarded. Multivariate outliers were identified using a regression model with Mahalanobis 
distance as an output, followed by comparison of the calculated Mahalanobis distances with the critical 
χ2 value for the dataset (Rasmussen 1988). One sample from the TejJ89 dataset for which the 
Mahalanobis distance exceeded the critical χ2 was discarded, leaving a total of n=286 samples to take 
forward for statistical testing. The characteristics of this final set of samples are summarised in Table 
1. 
 
2.7. Statistical analysis 
Differences in gene expression were tested using ANCOVA between 1) DR and AL feeding regimes 
and 2) TejJ89 and TejJ114 positive and negative responder strains under DR conditions. qRT-PCR 
plate was included as a co-variate in order to control for any batch effects across the 3 plates used for 
each gene expression assay. Linear regression models were then performed using DR status and 
responder strain as independent variables and including an interaction term to determine the presence 
of moderating effects between the two variables. ANCOVAs and regressions were carried out in 
STATA v15.1 (StataCorp, College Station, TX, USA). Benjamini, Krieger and Yekutieli false discovery 
rate (FDR) calculations (Benjamini and others 2006) were performed using GraphPad Prism 8.1.1 
(GraphPad Software, San Diego, CA, USA),  with the q-value set at 5%. 
 
3. Results 
3.1. Splicing factors demonstrate altered expression levels under DR conditions (‘DR 
associated factors’) 
We identified that several splicing factors displayed differential expression levels with short-term or 
long-term DR, and that these differences displayed striking tissue specificity (Fig 1, Supplementary 
Tables S2, S3 & S4). In brain, most of the expression changes we observed were associated with long-
term 40% DR, mainly in the positive responder strain TejJ89 and largely belonging to the Hnrnp class 
of splicing inhibitors. Expression levels of over half (9/16) of the splicing factors tested were significantly 
altered with DR at a nominal level, with 4 of these (Hnrnpa0, Hnrnpa1, Hnrnph3 and Hnrnpk) remaining 
statistically significant after correction for multiple testing. Conversely, following short-term 40% DR in 
brain, differences were seen equally frequently in positively and negatively responding strains and 
mainly involved Srsf splicing activators or core spliceosome components, although only one (Srsf6) 
met multiple testing criteria (Fig 2a & 2b). In heart, we identified most alterations in conjunction with 
short-term DR, with almost all differences being found in the negative responder strain TejJ114, 
involving both Srsf and Hnrnp splicing factors, the majority of which (Hnrnpa1, Hnrnpa2b1, Hnrnpd, 
Srsf6 and Sf1) were significant after correcting for multiple testing (Fig 3a & 3b). Finally, in kidney, as 
we saw in the heart, most of the changes we identified were in conjunction with short-term DR but 
occurred in both positively and negatively responsive strains. Differences found involved mainly Srsf 
splicing activators or core components of the spliceosome, and 5 out of 14 of these (Hnrnpa1, Srsf1, 
Srsf6, Tra2b and Sf1) remained significant after correction for multiple testing. (Fig 4a & 4b).  
 
3.2. Splicing factors demonstrate different patterns of expression with DR in positive and 
negative responder strains (‘strain-associated factors’) 
We next identified splicing factors that demonstrated differences in expression patterns between the 
positive and negative responder strains under short-term or long-term 40% DR. With the exception of 
brain, most of the differential expression levels in the two strains were present under short-term DR 
conditions (Supplementary Table S5). In brain, only expression of Hnrnpa0 and Srsf2 differed between 
strains under short-term DR, and only Srsf2 remained significant after correction for multiple testing 
(Fig 2a). Many more incidences where the positive and negative responder strains demonstrated 
differences in splicing factor expression were evident in brain in response to long-term DR; 11/16 genes 
exhibited differential expression between strains under these conditions, with 6 of these (Hnrnpa2b1, 
Hnrnpd, Hnrnph3, Hnrnpk, Srsf6 and Sf1) meeting the multiple testing threshold (Fig 2b). Several 
differences between strains were apparent in heart under conditions of short-term DR, which involved 
both Srsf and Hnrnp transcripts (Fig 3a), although only one of these (Hnrnpd) was significant when 
corrected for multiple testing. Fewer expression differences were apparent overall under long-term DR 
in heart (Fig 3b), however 2 of these (Hnrnpul2 and Srsf3) met multiple testing criteria. Kidney 
demonstrated fewer alterations than either brain or heart, with differences seen only in response to 
short-term DR, although 2 of these (Hnrnpa1 and Sf1) met the multiple testing threshold (Fig 4a & 4b). 
 
3.3. Expression levels of some splicing factors are associated with both lifespan effects and 
DR (‘interacting factors’) 
Some of the most interesting associations are those in which splicing factor expression is associated 
with both DR and strain. In such cases it is reasonable to postulate that those transcripts may be 
involved in pathways which contribute to the observed responses to 40% DR within each strain, but 
are also playing some part in the differences seen in strain-specific lifespan response, and so these 
splicing factors may comprise part of the molecular mechanism behind the response to DR. We 
therefore sought to identify situations where a statistical interaction was apparent between DR, strain 
and splicing factor expression (Supplementary Table S6). In brain, only Srsf2 displayed a nominal 
interaction under short-term DR conditions (Fig 2a), whereas under long-term DR, 9 of 16 splicing 
factors tested showed at least nominal interactions, with 4 of these (Hnrnpa1, Hnrnpa2b1, Hnrnph3 
and Hnrnpk) significant after correction for multiple testing (Fig 2b). In heart, far fewer interactions were 
apparent overall, with 3 of the 16 splicing factors having nominally significant interactions under short-
term DR (Fig 3a) and only 1 nominal interaction was detected under long-term DR conditions (Fig 3b), 
however none of these were significant after correction for multiple testing. Finally, in kidney tissue 
only 2 transcripts were found to show interactions, and only under conditions of short-term DR, with 
one of these (Sf1) meeting the criteria for multiple testing (Fig 4a & 4b). 
 
4. Discussion 
Lifespan extension as a result of dietary restriction (DR) has been recognised for over a century 
(McCay and others 1928; Osborne and others 1917) and has since been the subject of intensive 
research. The relationship between DR and lifespan is however sometimes unclear, with variation in 
the lifespan effect reported both across and within species (Liao and others 2010; Mockett and others 
2006; Rikke and others 2010; Selman and Swindell 2018; Speakman and Mitchell 2011). It is apparent 
therefore that our understanding of the mechanistic basis underpinning responses to DR is not 
complete, and that other influences exist which may explain some of the observed strain heterogeneity. 
One such influence may be the interface between the environmental stimulus (DR) and factors 
moderating the expression or activity of gene expression. While many such factors exist, one that is 
highly likely to play a part is alternative splicing, as it is a fundamental component of the response of 
cells to external and internal stimuli (Mastrangelo and others 2012), and components of the splicing 
machinery have previously been implicated in response to DR (Heintz and others 2017; Swindell 2009). 
Here, we have measured transcript expression levels of an a priori panel of age- or senescence-related 
splicing regulatory factors in brain, heart and kidney tissue taken from three ILSXISS recombinant 
inbred mouse strains with previously reported different lifespan responses to 40% DR. Animals were 
exposed to both short-term and long-term 40% DR and subsequent analyses were performed to 
characterise expression differences related to DR alone, differences only related to strain, and effects 
attributable to both. Our results show that expression levels of several splicing factor transcripts are 
significantly affected by either short-term or long-term DR, that there are significant differences in 
expression levels of some transcripts between positive and negative responder strains, and that there 
are strong tissue specific influences on both effects. Furthermore, some splicing factors demonstrate 
statistical interactions between their expression, DR and strain lifespan response, which may indicate 
mechanistic involvement in the divergent lifespan response to DR observed in these mouse strains 
under DR conditions. 
Dietary restriction has been shown to be linked to lifespan, with multiple pathways involved including 
those involved in genomic stability, proteostasis, inflammation, autophagy, mitochondrial function, 
oxidative damage and nutrient signalling pathways (IIS, IGF-1, SIRT, AMKP and mTOR) (Kenyon 
2010; Picca and others 2017). It is known that the ability to respond to internal and external sources of 
cellular stress is an important factor in successful ageing (Kourtis and Tavernarakis 2011), and that 
transcriptomic responsiveness plays a large part in this, including the plasticity of response that is 
achieved through alternative splicing (Kelemen and others 2013). A recent study has shown that the 
splicing factor SF1 is necessary for lifespan extension by DR in C. elegans, specifically through the 
modulation of TORC1 pathway components (Heintz and others 2017). Our previous work has shown 
that both alternative splicing and more specifically the expression levels of splicing regulatory factors 
that control it, are associated with ageing in humans (Harries and others 2011), cellular senescence in 
vitro (Holly and others 2013; Latorre and others 2018b) and lifespan in animal models (Lee and others 
2016). Recently we also showed that alteration of splicing factor levels using small molecules such as 
resveratrol analogues, hydrogen sulfide donors or inhibitors of ERK or AKT signalling can reverse 
senescence phenotypes in vitro (Latorre and others 2017; Latorre and others 2018a; Latorre and others 
2018c). Given this evidence, it is reasonable to hypothesise that regulation of alternative splicing may 
play a role in the lifespan modification response following DR.  
The results presented here are consistent with a hypothesis that altered splicing regulation may form 
part of the mechanistic response to DR in mice. We propose that the splicing factors we tested can be 
classified into three broad classes: 1) DR-associated factors. Expression of these splicing factors is 
significantly affected by DR, but no differences are apparent between strains, suggesting that although 
they may have some association to DR, they are unlikely to contribute to any strain-specific differences 
seen in the DR response. 2) Strain-associated factors. Expression of these splicing factors is 
significantly different between strains but do not differ between AL and DR. 3) Interacting factors. 
Splicing factors showing statistically significant interactions between DR and strain lifespan response 
in terms of their expression. Where such interactions exist, the associations between splicing factor 
expression and either DR or responder strain (or both), coupled with a statistically significant mediation 
effect between the two variables (Fig 5), suggests that these splicing factors may be mechanistically 
involved in defining the divergent lifespan response observed in these mouse strains under 40% DR. 
Splicing factors showing statistical interactions between strain and DR were very common in brain, 
particularly in response to long term DR. This may reflect a more pressing need for the brain to 
moderate gene output to maintain homeostatic control than is necessary in the other tissues. It is 
interesting to note that within the splicing factors affected in the brain, a preponderance of the 
differences noted between AL and DR (7 out of 8) are observed in the positive responder strain while 
only 3 of 8 are altered in the negative responder. Few associations were shared between tissues, with 
only Srsf6 and Hnrnpa1 showing patterns that were shared between brain and heart (Srsf6) or brain 
and kidney (Hnrnpa1).  
Our study has several strengths, including a comprehensive assessment of strain-, tissue- and duration 
effects. There are of course also limitations to this work; it would have been advantageous to measure 
alternative isoform expression of target genes of these splicing factors to determine whether they could 
actively be affecting alternative splicing. Another caveat to the work is that optimally, protein levels of 
splicing factors would be informative. Unfortunately this was not possible due to limits on starting 
material. We have used an FDR approach to account for multiple testing, following the two-stage linear 
step-up procedure of Benjamini, Krieger and Yekutieli (Benjamini and others 2006). However, it must 
be recognised that although relatively modest, correlations do exist between expression levels of many 
splicing factors (Fig 6) and that further correlations are likely to exist between different DR treatments 
and indeed to an extent between the different mouse strains. All of this suggests that the tests 
performed here are not completely independent, which in turn greatly complicates any sensible 
application of multiple testing criteria. In addition, while groups of 8 animals per condition is reasonable 
for a study of this type, there may be an impact on statistical power which could result in Type II errors. 
Therefore, we recognise that the multiple testing threshold applied here may be overly severe, and as 
such have presented nominal findings alongside those which are FDR-corrected, although we 
recognise that careful interpretation must be applied to such results. 
In summary, this study has shown that the expression of splicing factor transcripts shows widespread 
alterations in response to dietary restriction, and that these are highly tissue specific. It is also apparent 
that certain transcripts show interactions between the effects of DR, expression levels and strain 
lifespan response, which could therefore be involved in the mechanisms driving lifespan modulation 
via DR.  
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Table 1. Details of mice used in the study. 
Shown here are the numbers of animals included in each feeding regime and diet for each tissue in 
each strain of mouse used in the current study. 
 
 
  
Strain Tissue Diet Regime n 
TejJ48 
Brain 
AL 
2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 7 
DR 
2 month 8 
10 month 8 
Kidney 
AL 
2 month 7 
10 month 8 
DR 
2 month 7 
10 month 8 
TejJ89 
Brain 
AL 
2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 8 
DR 
2 month 9 
10 month 8 
Kidney 
AL 
2 month 8 
10 month 10 
DR 
2 month 8 
10 month 6 
TejJ114 
Brain 
AL 
2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Heart 
AL 
2 month 8 
10 month 8 
DR 
2 month 8 
10 month 8 
Kidney 
AL 
2 month 8 
10 month 7 
DR 
2 month 9 
10 month 8 
Figure Legends 
Figure 1: Tissue-specificity of splicing factor expression under 40% DR conditions 
Heatmaps depicting post-ANCOVA marginal effects for log fold-change in 40% DR expression levels 
of each transcript (when compared to AL). Data from short-term and long-term 40% DR regimes are 
shown for each tissue separately. Panel a shows data for the positive responder (TejJ89) and panel b 
for the negative responder (TejJ114). Transcripts up-regulated in 40% DR are shown in green while 
those that are down-regulated are shown in red. 
Figure 2: Effects of 40% DR on splicing factor expression in brain tissue 
Shown here are transcript expression levels in ILSXISS mouse brain tissue under short-term and long-
term DR conditions. Panel a shows expression under short-term 40% DR, panel b shows expression 
under long-term 40% DR. Plots show post-estimation marginal effects from the linear regressions used 
for interaction analysis. Data points represent log fold-change in DR expression levels of each 
transcript (when compared to AL), separately for the two mouse strains. Significant differences are 
denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars indicated in black denote 
associations which meet the multiple testing threshold, while those in grey represent nominal 
associations. Data for the positive responder strain (TejJ89) is shown as solid points and line in black, 
while the negative responder strain (TejJ114) is shown as open points and dashed line in grey. The 
null point is indicated by a dotted line. Error bars represent 95% confidence intervals. 
Figure 3: Effects of 40% DR on splicing factor expression in heart tissue 
Shown here are transcript expression levels in ILSXISS mouse heart tissue under short-term and long-
term DR conditions. Panel a shows expression under short-term 40% DR, panel b shows expression 
under long-term 40% DR. Plots show post-estimation marginal effects from the linear regressions used 
for interaction analysis. Data points represent log fold-change in DR expression levels of each 
transcript (when compared to AL), separately for the two mouse strains. Significant differences are 
denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars indicated in black denote 
associations which meet the multiple testing threshold, while those in grey represent nominal 
associations Data for the positive responder strain (TejJ89) is shown as solid points and line in black, 
while the negative responder strain (TejJ114) is shown as open points and dashed line in grey. The 
null point is indicated by a dotted line. Error bars represent 95% confidence intervals. 
Figure 4: Effects of 40% DR on splicing factor expression in kidney tissue 
Shown here are transcript expression levels in ILSXISS mouse kidney tissue under short-term and 
long-term DR conditions. Panel a shows expression under short-term 40% DR, panel b shows 
expression under long-term 40% DR. Plots show post-estimation marginal effects from the linear 
regressions used for interaction analysis. Data points represent log fold-change in DR expression 
levels of each transcript (when compared to AL), separately for the two mouse strains. Significant 
differences are denoted with stars:  = p<0.05,  = p<0.01,  = p<0.001. Stars indicated in black 
denote associations which meet the multiple testing threshold, while those in grey represent nominal 
associations. Data for the positive responder strain (TejJ89) is shown as solid points and line in black, 
while the negative responder strain (TejJ114) is shown as open points and dashed line in grey. The 
null point is indicated by a dotted line. Error bars represent 95% confidence intervals. 
Figure 5: Directionality of effects and potential moderating interactions 
This figure shows the likely interplay between the variables measured in the present study. Direct 
effects are shown as solid black arrows, while interactions where one variable could be moderating the 
effect exerted between other variables are shown as dashed grey arrows. 
Figure 6: Correlations between splicing factor expression levels 
Pearson correlations of relationships between expression levels of all splicing factors measured. 
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Supplementary information 
Supplementary Figure S1: Changes in splicing factor expression in non-responder strain 
(TejJ48) under DR conditions 
Plots illustrating changes in splicing factor expression with DR in the non-responder strain of ILSXISS 
mice (TejJ48). Plot a shows mean differences between AL and DR in brain tissue under short-term 
DR, b shows mean differences between AL and DR in brain tissue under long-term DR, c shows mean 
differences between AL and DR in heart tissue under short-term DR, d shows mean differences 
between AL and DR in heart tissue under long-term DR, e shows mean differences between AL and 
DR in kidney tissue under short-term DR and f shows mean differences between AL and DR in kidney 
tissue under long-term DR. Error bars represent 95% confidence intervals and significant differences 
in splicing factor expression are denoted by stars:  = p<0.05. 
 
 
 
Supplementary Table S1:  Taqman® Assays. 
Splicing factor target genes, assay IDs and qPCR software settings for each transcript included in the 
current study.  Endogenous control genes used are shown in bold italics. 
Target Assay ID Threshold Baseline Start Baseline End 
Hnrnpa0 Mm03809085_s1 0.075 3 22 
Hnrnpa1 Mm02528230_g1 0.098 3 18 
Hnrnpa2b1 Mm01325931_g1 0.145 3 18 
Hnrnpd Mm01201314_m1 0.112 3 21 
Hnrnph3 Mm01032120_g1 0.095 3 24 
Hnrnpk Mm01349462_m1 0.129 3 18 
Hnrnpm Mm00513070_m1 0.068 3 21 
Hnrnpul2 Mm01230949_m1 0.114 3 21 
Pnisr Mm01219239_m1 0.052 3 20 
Srsf1 Mm00557620_m1 0.123 3 21 
Srsf2 Mm00448705_m1 0.040 3 20 
Srsf3 Mm00786953_s1 0.044 3 23 
Srsf6 Mm00471475_m1 0.074 3 21 
Tra2b Mm00833637_mH 0.031 3 21 
Sf1 Mm00496060_m1 0.104 3 19 
Sf3b1 Mm00473100_m1 0.044 3 19 
Gusb Mm01197698_m1 0.092 3 21 
Idh3b Mm00504589_m1 0.112 3 18 
Ppia Mm03024003_g1 0.068 3 17 
Supplementary Table S2: Changes in splicing factor expression with long-term and short-term 
40% DR in non-responder mice. 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissues from mice which display no change in lifespan under 40% DR conditions (TejJ89), by 
ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 0.360 0.203 0.102 0.803 -0.083 0.188 0.208 0.383 0.641 -0.264 
Hnrnpa1 0.326 0.187 0.109 0.739 -0.086 -0.175 0.204 0.407 0.269 -0.619 
Hnrnpa2b1 0.029 0.192 0.882 0.447 -0.389 0.161 0.113 0.182 0.408 -0.086 
Hnrnpd 0.200 0.121 0.123 0.463 -0.063 0.194 0.121 0.136 0.459 -0.070 
Hnrnph3 -0.192 0.135 0.181 0.103 -0.487 -0.063 0.161 0.701 0.287 -0.413 
Hnrnpk 0.082 0.112 0.482 0.329 -0.165 -0.131 0.131 0.335 0.153 -0.416 
Hnrnpm -0.220 0.211 0.318 0.240 -0.679 0.150 0.136 0.293 0.447 -0.147 
Hnrnpul2 0.027 0.121 0.830 0.291 -0.238 0.179 0.125 0.178 0.451 -0.094 
Pnisr -0.181 0.161 0.284 0.171 -0.532 0.305 0.186 0.126 0.709 -0.099 
Srsf1 -0.257 0.235 0.294 0.254 -0.769 0.044 0.144 0.766 0.357 -0.270 
Srsf2 -0.130 0.168 0.456 0.237 -0.496 -0.157 0.186 0.414 0.248 -0.562 
Srsf3 0.283 0.137 0.063 0.584 -0.018 -0.252 0.197 0.225 0.177 -0.681 
Srsf6 0.837 0.297 0.015 1.483 0.190 -0.187 0.251 0.470 0.359 -0.734 
Tra2b -0.190 0.133 0.179 0.100 -0.480 -0.188 0.100 0.085 0.030 -0.406 
C
o
re
 
Sf1 0.232 0.163 0.183 0.590 -0.127 -0.070 0.146 0.638 0.247 -0.388 
Sf3b1 -0.170 0.168 0.330 0.195 -0.536 -0.162 0.191 0.414 0.255 -0.578 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.135 0.111 0.249 0.108 -0.378 0.077 0.161 0.642 0.430 -0.277 
Hnrnpa1 -0.115 0.146 0.448 0.204 -0.433 0.112 0.190 0.566 0.531 -0.306 
Hnrnpa2b1 0.135 0.158 0.411 0.480 -0.210 -0.205 0.121 0.119 0.062 -0.473 
Hnrnpd 0.115 0.104 0.292 0.341 -0.112 -0.029 0.117 0.810 0.228 -0.286 
Hnrnph3 0.000 0.114 0.997 0.247 -0.248 0.056 0.113 0.630 0.303 -0.192 
Hnrnpk -0.065 0.153 0.681 0.269 -0.398 -0.156 0.157 0.340 0.189 -0.501 
Hnrnpm -0.195 0.193 0.332 0.225 -0.615 -0.029 0.080 0.721 0.149 -0.208 
Hnrnpul2 0.003 0.104 0.980 0.230 -0.224 -0.096 0.196 0.632 0.334 -0.527 
Pnisr 0.023 0.102 0.826 0.244 -0.199 0.109 0.171 0.535 0.485 -0.266 
Srsf1 -0.020 0.297 0.948 0.627 -0.666 0.280 0.290 0.355 0.918 -0.358 
Srsf2 -0.109 0.131 0.423 0.176 -0.394 0.208 0.154 0.205 0.547 -0.132 
Srsf3 0.113 0.142 0.439 0.422 -0.195 0.318 0.171 0.091 0.695 -0.059 
Srsf6 0.143 0.210 0.511 0.601 -0.316 0.020 0.212 0.928 0.487 -0.448 
Tra2b -0.086 0.093 0.375 0.117 -0.288 -0.091 0.143 0.541 0.229 -0.410 
C
o
re
 
Sf1 -0.239 0.190 0.232 0.174 -0.652 -0.219 0.213 0.327 0.250 -0.687 
Sf3b1 -0.021 0.175 0.905 0.363 -0.406 -0.048 0.214 0.826 0.423 -0.519 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.371 0.176 0.064 0.027 -0.769 0.028 0.199 0.891 0.462 -0.406 
Hnrnpa1 0.263 0.143 0.096 0.581 -0.056 0.141 0.130 0.300 0.426 -0.143 
Hnrnpa2b1 -0.137 0.153 0.395 0.210 -0.483 0.117 0.145 0.436 0.435 -0.201 
Hnrnpd -0.230 0.155 0.168 0.115 -0.575 -0.196 0.086 0.041 -0.010 -0.383 
Hnrnph3 -0.182 0.151 0.254 0.154 -0.519 0.088 0.174 0.624 0.467 -0.292 
Hnrnpk -0.360 0.165 0.054 0.007 -0.727 -0.082 0.074 0.290 0.079 -0.242 
Hnrnpm -0.047 0.213 0.829 0.428 -0.522 -0.129 0.090 0.178 0.067 -0.325 
Hnrnpul2 -0.101 0.256 0.703 0.469 -0.671 -0.403 0.134 0.011 -0.112 -0.695 
Pnisr 0.237 0.182 0.222 0.643 -0.169 -0.170 0.103 0.124 0.054 -0.394 
Srsf1 -0.148 0.141 0.316 0.165 -0.461 -0.016 0.100 0.874 0.202 -0.235 
Srsf2 0.316 0.191 0.128 0.740 -0.109 0.299 0.102 0.012 0.521 0.077 
Srsf3 -0.035 0.231 0.882 0.479 -0.549 0.154 0.165 0.367 0.513 -0.205 
Srsf6 -0.179 0.202 0.398 0.272 -0.630 0.093 0.133 0.500 0.383 -0.198 
Tra2b -0.424 0.225 0.089 0.077 -0.925 -0.041 0.136 0.769 0.255 -0.336 
C
o
re
 
Sf1 0.420 0.145 0.016 0.744 0.097 0.178 0.132 0.202 0.465 -0.109 
Sf3b1 0.400 0.151 0.025 0.737 0.063 -0.092 0.137 0.514 0.206 -0.390 
Supplementary Table S3: Changes in splicing factor expression with long-term and short-term 
40% DR in positive responder mice. 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissues from mice which display lifespan extension under 40% DR conditions (TejJ89), by 
ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined, those which meet correction for multiple testing (p<0.0045) are shown 
in bold italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.424 0.252 0.119 -0.974 0.126 -0.954 0.235 0.002 -1.478 -0.429 
Hnrnpa1 -0.240 0.187 0.223 -0.647 0.167 1.554 0.389 0.004 0.658 2.450 
Hnrnpa2b1 0.128 0.125 0.324 -0.143 0.400 0.508 0.228 0.047 0.007 1.009 
Hnrnpd 0.021 0.179 0.909 -0.370 0.412 0.360 0.204 0.106 -0.090 0.810 
Hnrnph3 0.085 0.135 0.542 -0.210 0.380 -1.595 0.293 <0.001 -2.272 -0.918 
Hnrnpk -0.312 0.179 0.107 -0.703 0.079 1.512 0.343 0.002 0.736 2.287 
Hnrnpm 0.061 0.164 0.717 -0.296 0.418 -0.167 0.195 0.409 -0.597 0.262 
Hnrnpul2 0.039 0.134 0.777 -0.254 0.331 0.122 0.142 0.407 -0.190 0.435 
Pnisr 0.078 0.168 0.651 -0.287 0.443 0.024 0.268 0.929 -0.566 0.615 
Srsf1 0.316 0.214 0.166 -0.150 0.783 -0.828 0.272 0.011 -1.427 -0.229 
Srsf2 -0.187 0.139 0.202 -0.489 0.115 -0.510 0.390 0.220 -1.379 0.359 
Srsf3 -0.433 0.128 0.005 -0.712 -0.154 -1.020 0.507 0.079 -2.189 0.148 
Srsf6 -0.674 0.220 0.010 -1.153 -0.195 -0.742 0.363 0.065 -1.540 0.056 
Tra2b 0.100 0.091 0.290 -0.097 0.298 0.160 0.159 0.335 -0.189 0.510 
C
o
re
 
Sf1 -0.290 0.126 0.040 -0.564 -0.016 -0.637 0.188 0.007 -1.055 -0.219 
Sf3b1 0.373 0.155 0.033 0.035 0.710 0.737 0.254 0.016 0.172 1.302 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.331 0.180 0.089 -0.720 0.058 0.091 0.158 0.574 -0.254 0.436 
Hnrnpa1 0.210 0.199 0.310 -0.219 0.639 -0.208 0.156 0.206 -0.548 0.132 
Hnrnpa2b1 -0.022 0.109 0.841 -0.257 0.212 0.287 0.129 0.046 0.006 0.569 
Hnrnpd -0.017 0.115 0.884 -0.265 0.231 0.169 0.120 0.184 -0.092 0.431 
Hnrnph3 -0.123 0.086 0.173 -0.309 0.062 -0.007 0.157 0.964 -0.349 0.334 
Hnrnpk 0.234 0.191 0.244 -0.180 0.647 0.142 0.151 0.367 -0.188 0.471 
Hnrnpm -0.149 0.293 0.621 -0.783 0.485 -0.127 0.137 0.372 -0.425 0.171 
Hnrnpul2 -0.126 0.151 0.420 -0.453 0.201 -0.266 0.195 0.197 -0.692 0.159 
Pnisr -0.402 0.135 0.011 -0.694 -0.110 -0.156 0.177 0.396 -0.541 0.229 
Srsf1 -0.241 0.235 0.323 -0.748 0.266 0.004 0.269 0.988 -0.581 0.589 
Srsf2 0.171 0.178 0.353 -0.212 0.555 0.115 0.175 0.523 -0.266 0.496 
Srsf3 -0.103 0.135 0.458 -0.396 0.189 -0.051 0.131 0.704 -0.336 0.234 
Srsf6 -0.064 0.201 0.753 -0.498 0.369 0.607 0.220 0.017 0.128 1.086 
Tra2b 0.230 0.130 0.100 -0.051 0.511 0.220 0.181 0.247 -0.174 0.614 
C
o
re
 
Sf1 -0.147 0.155 0.361 -0.482 0.188 0.044 0.111 0.702 -0.198 0.285 
Sf3b1 0.323 0.300 0.301 -0.326 0.972 -0.160 0.166 0.355 -0.522 0.202 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 0.203 0.214 0.362 -0.264 0.669 0.152 0.088 0.108 -0.039 0.343 
Hnrnpa1 -0.438 0.093 <0.001 -0.640 -0.237 -0.332 0.216 0.150 -0.803 0.138 
Hnrnpa2b1 -0.158 0.085 0.086 -0.343 0.026 -0.205 0.196 0.315 -0.632 0.221 
Hnrnpd 0.063 0.087 0.483 -0.129 0.256 0.012 0.132 0.928 -0.276 0.301 
Hnrnph3 -0.085 0.075 0.277 -0.248 0.078 -0.627 0.212 0.012 -1.088 -0.166 
Hnrnpk -0.025 0.066 0.715 -0.169 0.119 -0.020 0.150 0.898 -0.346 0.307 
Hnrnpm 0.330 0.140 0.037 0.024 0.635 0.098 0.195 0.625 -0.327 0.522 
Hnrnpul2 -0.237 0.105 0.043 -0.465 -0.008 -0.192 0.161 0.258 -0.545 0.162 
Pnisr -0.289 0.121 0.034 -0.552 -0.026 0.522 0.149 0.004 0.198 0.846 
Srsf1 0.133 0.066 0.068 -0.012 0.278 -0.189 0.057 0.006 -0.314 -0.064 
Srsf2 0.069 0.101 0.509 -0.151 0.288 0.353 0.232 0.155 -0.153 0.859 
Srsf3 0.094 0.160 0.569 -0.256 0.444 -0.186 0.180 0.322 -0.578 0.206 
Srsf6 0.692 0.144 <0.001 0.378 1.005 0.054 0.175 0.763 -0.327 0.435 
Tra2b 0.343 0.109 0.008 0.106 0.580 -0.265 0.173 0.152 -0.641 0.112 
C
o
re
 
Sf1 0.064 0.115 0.592 -0.188 0.315 0.147 0.122 0.251 -0.118 0.413 
Sf3b1 -0.327 0.150 0.049 -0.653 -0.001 0.328 0.151 0.050 0.000 0.656 
Supplementary Table S4: Changes in splicing factor expression with long-term and short-term 
40% DR in negative responder mice. 
Changes in splicing factor expression levels with long-term and short-term DR in brain, heart and 
kidney tissue from mice which display lifespan reduction under 40% DR conditions (TejJ114), by 
ANCOVA. A positive mean difference denotes an increase in expression levels under 40% DR 
conditions when compared to AL feeding. Transcripts showing nominal associations (p<0.05) are 
shown in italic and underlined, those which meet correction for multiple testing (p<0.0045) are shown 
in bold italic and underlined. SE: standard error, 95% CI: 95% confidence intervals. 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 0.062 0.200 0.761 -0.373 0.497 0.258 0.332 0.453 -0.472 0.988 
Hnrnpa1 0.032 0.215 0.886 -0.436 0.499 -0.254 0.314 0.435 -0.937 0.430 
Hnrnpa2b1 0.268 0.114 0.037 0.019 0.517 -0.437 0.153 0.014 -0.769 -0.104 
Hnrnpd 0.093 0.116 0.436 -0.158 0.345 -0.462 0.186 0.028 -0.867 -0.058 
Hnrnph3 0.089 0.100 0.392 -0.129 0.307 -0.342 0.151 0.043 -0.670 -0.013 
Hnrnpk -0.281 0.159 0.102 -0.627 0.065 -0.196 0.269 0.481 -0.781 0.390 
Hnrnpm 0.010 0.147 0.949 -0.310 0.329 0.163 0.255 0.535 -0.393 0.719 
Hnrnpul2 0.112 0.086 0.214 -0.074 0.298 -0.193 0.166 0.266 -0.554 0.168 
Pnisr -0.008 0.174 0.965 -0.388 0.372 0.123 0.184 0.517 -0.278 0.524 
Srsf1 -0.247 0.317 0.453 -0.945 0.451 0.222 0.235 0.365 -0.291 0.734 
Srsf2 0.348 0.157 0.046 0.007 0.689 0.237 0.277 0.408 -0.366 0.840 
Srsf3 -0.334 0.184 0.094 -0.735 0.067 0.172 0.204 0.417 -0.273 0.616 
Srsf6 -0.808 0.208 0.002 -1.262 -0.354 0.261 0.149 0.105 -0.064 0.586 
Tra2b -0.037 0.102 0.727 -0.259 0.186 0.156 0.189 0.427 -0.257 0.568 
C
o
re
 
Sf1 -0.407 0.125 0.007 -0.680 -0.134 -0.023 0.213 0.916 -0.487 0.441 
Sf3b1 0.417 0.213 0.074 -0.047 0.882 -0.009 0.340 0.979 -0.750 0.732 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 0.067 0.174 0.705 -0.312 0.447 -0.344 0.099 0.005 -0.561 -0.127 
Hnrnpa1 0.407 0.113 0.004 0.161 0.653 -0.236 0.170 0.189 -0.606 0.134 
Hnrnpa2b1 -0.287 0.073 0.002 -0.448 -0.127 0.258 0.151 0.114 -0.071 0.587 
Hnrnpd -0.316 0.087 0.003 -0.505 -0.127 0.005 0.156 0.975 -0.334 0.344 
Hnrnph3 0.010 0.077 0.895 -0.158 0.178 -0.015 0.116 0.899 -0.268 0.238 
Hnrnpk -0.006 0.165 0.971 -0.365 0.353 0.368 0.181 0.066 -0.028 0.763 
Hnrnpm 0.567 0.187 0.011 0.158 0.975 -0.221 0.249 0.393 -0.763 0.321 
Hnrnpul2 -0.202 0.135 0.159 -0.495 0.091 0.275 0.126 0.049 0.001 0.550 
Pnisr 0.060 0.166 0.724 -0.305 0.425 0.043 0.120 0.725 -0.218 0.304 
Srsf1 0.054 0.189 0.779 -0.357 0.465 -0.079 0.126 0.543 -0.353 0.196 
Srsf2 0.460 0.166 0.017 0.099 0.821 0.071 0.111 0.531 -0.170 0.313 
Srsf3 0.147 0.205 0.489 -0.301 0.594 -0.005 0.107 0.967 -0.240 0.231 
Srsf6 -0.685 0.151 <0.001 -1.014 -0.355 0.318 0.151 0.057 -0.012 0.648 
Tra2b 0.092 0.144 0.534 -0.221 0.405 0.338 0.195 0.109 -0.088 0.763 
C
o
re
 
Sf1 -0.511 0.138 0.003 -0.812 -0.211 -0.342 0.187 0.092 -0.750 0.065 
Sf3b1 -0.259 0.205 0.230 -0.705 0.188 -0.305 0.253 0.252 -0.857 0.247 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 0.147 0.195 0.466 -0.276 0.569 0.202 0.194 0.320 -0.225 0.630 
Hnrnpa1 -0.129 0.100 0.216 -0.345 0.086 -0.325 0.125 0.025 -0.600 -0.050 
Hnrnpa2b1 -0.105 0.129 0.433 -0.384 0.175 -0.419 0.125 0.007 -0.698 -0.140 
Hnrnpd -0.095 0.098 0.350 -0.307 0.117 0.013 0.103 0.905 -0.214 0.239 
Hnrnph3 -0.122 0.111 0.293 -0.362 0.118 -0.345 0.201 0.120 -0.800 0.110 
Hnrnpk 0.198 0.128 0.146 -0.079 0.474 0.134 0.170 0.448 -0.240 0.507 
Hnrnpm 0.148 0.109 0.196 -0.087 0.384 -0.054 0.215 0.805 -0.527 0.419 
Hnrnpul2 -0.314 0.135 0.037 -0.605 -0.022 0.171 0.129 0.212 -0.113 0.454 
Pnisr -0.261 0.144 0.094 -0.573 0.051 0.182 0.224 0.432 -0.310 0.674 
Srsf1 0.285 0.073 0.002 0.128 0.442 -0.015 0.081 0.857 -0.193 0.164 
Srsf2 0.151 0.139 0.297 -0.149 0.451 0.048 0.134 0.728 -0.247 0.343 
Srsf3 0.456 0.140 0.006 0.155 0.758 0.126 0.218 0.574 -0.354 0.606 
Srsf6 0.449 0.177 0.025 0.066 0.832 0.283 0.191 0.168 -0.139 0.704 
Tra2b 0.487 0.119 0.001 0.228 0.746 0.015 0.307 0.961 -0.660 0.691 
C
o
re
 
Sf1 -0.495 0.104 <0.001 -0.720 -0.270 0.173 0.145 0.257 -0.145 0.491 
Sf3b1 -0.557 0.168 0.005 -0.919 -0.195 0.223 0.204 0.297 -0.225 0.672 
Supplementary Table S5:  Splicing factor expression according to mouse strain. 
Differences in splicing factor expression between the lifespan extension (TejJ89) and lifespan reduction 
(TejJ114) responder strains under 40% DR by ANCOVA. A positive mean difference denotes higher 
expression levels in TejJ89 relative to TejJ114 under 40% DR conditions. Transcripts showing nominal 
associations (p<0.05) are shown in italic and underlined, those which meet correction for multiple 
testing (p<0.0045) are shown in bold italic and underlined. SE: standard error, 95% CI: 95% confidence 
intervals. 
  Brain – Short-term DR Brain – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.446 0.170 0.022 -0.816 -0.077 -1.150 0.358 0.011 -1.960 -0.340 
Hnrnpa1 0.089 0.208 0.675 -0.364 0.542 1.788 0.510 0.008 0.613 2.963 
Hnrnpa2b1 -0.044 0.156 0.780 -0.384 0.295 0.963 0.199 <0.001 0.526 1.400 
Hnrnpd 0.032 0.127 0.808 -0.245 0.309 0.825 0.215 0.003 0.351 1.300 
Hnrnph3 -0.105 0.125 0.418 -0.377 0.168 -1.289 0.314 0.003 -2.014 -0.565 
Hnrnpk 0.102 0.160 0.534 -0.246 0.450 1.691 0.411 0.003 0.761 2.621 
Hnrnpm -0.281 0.148 0.082 -0.604 0.041 -0.200 0.264 0.465 -0.780 0.381 
Hnrnpul2 -0.017 0.109 0.876 -0.254 0.220 0.309 0.109 0.016 0.070 0.549 
Pnisr -0.119 0.160 0.471 -0.468 0.230 0.144 0.190 0.465 -0.274 0.562 
Srsf1 0.229 0.278 0.426 -0.377 0.836 -0.881 0.294 0.012 -1.528 -0.234 
Srsf2 -0.533 0.133 0.002 -0.823 -0.243 -0.801 0.371 0.056 -1.628 0.026 
Srsf3 -0.219 0.135 0.131 -0.513 0.076 -1.281 0.431 0.018 -2.274 -0.288 
Srsf6 -0.084 0.227 0.718 -0.578 0.410 -1.180 0.286 0.002 -1.810 -0.550 
Tra2b 0.008 0.103 0.940 -0.216 0.231 -0.119 0.143 0.424 -0.434 0.196 
C
o
re
 
Sf1 0.186 0.138 0.204 -0.115 0.487 -0.687 0.184 0.004 -1.098 -0.276 
Sf3b1 0.245 0.155 0.141 -0.094 0.584 0.715 0.398 0.103 -0.172 1.602 
  Heart – Short-term DR Heart – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.374 0.165 0.041 -0.731 -0.017 0.516 0.175 0.012 0.134 0.899 
Hnrnpa1 -0.039 0.164 0.817 -0.393 0.316 -0.230 0.167 0.194 -0.593 0.134 
Hnrnpa2b1 0.194 0.130 0.162 -0.089 0.478 -0.015 0.108 0.893 -0.249 0.220 
Hnrnpd 0.344 0.088 0.002 0.154 0.534 0.107 0.121 0.393 -0.156 0.371 
Hnrnph3 -0.168 0.093 0.096 -0.369 0.034 -0.001 0.130 0.996 -0.284 0.283 
Hnrnpk 0.214 0.163 0.211 -0.138 0.566 -0.093 0.146 0.535 -0.412 0.225 
Hnrnpm -0.733 0.255 0.013 -1.283 -0.183 0.159 0.243 0.526 -0.371 0.690 
Hnrnpul2 0.056 0.158 0.731 -0.286 0.397 -0.572 0.134 0.001 -0.863 -0.282 
Pnisr -0.457 0.183 0.028 -0.856 -0.058 -0.248 0.139 0.099 -0.550 0.054 
Srsf1 -0.338 0.144 0.035 -0.648 -0.028 0.165 0.217 0.462 -0.307 0.636 
Srsf2 -0.224 0.173 0.219 -0.599 0.151 0.073 0.144 0.624 -0.241 0.386 
Srsf3 -0.248 0.152 0.126 -0.576 0.080 0.359 0.093 0.002 0.156 0.561 
Srsf6 0.425 0.172 0.028 0.053 0.797 0.429 0.177 0.032 0.043 0.815 
Tra2b 0.022 0.177 0.904 -0.361 0.404 0.034 0.156 0.834 -0.307 0.374 
C
o
re
 
Sf1 0.191 0.169 0.279 -0.175 0.557 0.402 0.183 0.048 0.005 0.800 
Sf3b1 0.657 0.234 0.015 0.151 1.162 0.008 0.231 0.974 -0.495 0.510 
  Kidney – Short-term DR Kidney – Long-term DR 
    
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Mean 
Difference SE p-value 
95% CI 
lower 
95% CI 
upper 
Sp
lic
in
g 
Fa
ct
o
rs
 
Hnrnpa0 -0.013 0.208 0.950 -0.463 0.436 -0.264 0.153 0.115 -0.604 0.076 
Hnrnpa1 -0.371 0.092 0.001 -0.569 -0.173 -0.206 0.156 0.217 -0.554 0.142 
Hnrnpa2b1 -0.065 0.150 0.672 -0.389 0.259 -0.001 0.156 0.996 -0.354 0.352 
Hnrnpd 0.123 0.089 0.191 -0.070 0.316 -0.022 0.120 0.856 -0.289 0.245 
Hnrnph3 0.055 0.103 0.605 -0.169 0.278 -0.148 0.247 0.566 -0.718 0.422 
Hnrnpk -0.151 0.132 0.274 -0.436 0.135 0.229 0.148 0.154 -0.101 0.559 
Hnrnpm 0.188 0.111 0.114 -0.051 0.427 0.193 0.237 0.435 -0.335 0.721 
Hnrnpul2 0.093 0.147 0.538 -0.224 0.410 -0.177 0.153 0.274 -0.518 0.164 
Pnisr -0.059 0.149 0.698 -0.381 0.263 0.259 0.160 0.136 -0.097 0.614 
Srsf1 -0.174 0.086 0.065 -0.361 0.012 -0.089 0.100 0.394 -0.311 0.133 
Srsf2 -0.112 0.116 0.352 -0.362 0.138 0.282 0.224 0.236 -0.217 0.781 
Srsf3 -0.280 0.115 0.030 -0.528 -0.033 -0.006 0.234 0.979 -0.527 0.514 
Srsf6 0.279 0.186 0.157 -0.122 0.681 0.072 0.143 0.627 -0.247 0.390 
Tra2b -0.059 0.090 0.525 -0.254 0.137 0.096 0.263 0.724 -0.491 0.682 
C
o
re
 
Sf1 0.552 0.116 <0.001 0.301 0.802 -0.031 0.112 0.785 -0.281 0.218 
Sf3b1 0.178 0.160 0.285 -0.167 0.524 -0.102 0.187 0.597 -0.520 0.315 
Supplementary Table S6: Interactions between strain effects and 40% DR effects on 1 
splicing factor expression. 2 
Shown here are the interaction coefficients between strain effects and DR effects on splicing 3 
factor transcript expression. A positive coefficient denotes combinatorial effects contributing 4 
to higher expression levels in TejJ89 relative to TejJ114 under 40% DR conditions. Also shown 5 
are the postestimation marginal effects for each strain. Positive margins denote an increase 6 
in expression levels in the respective strain under 40% DR conditions when compared to AL 7 
feeding. Transcripts showing nominal associations (p<0.05) are shown in italic and underlined, 8 
those which meet correction for multiple testing (p<0.0045) are shown in bold italic and 9 
underlined. SE: standard error, 95% CI: 95% confidence intervals. 10 
Brain – Short-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient -0.495 0.308 -1.128 0.138 0.120 
 TejJ89 – Marginal effect -0.407 0.148 -0.711 -0.103  
 TejJ114 – Marginal 
effect 0.056 0.149 -0.251 0.362  
Hnrnpa1 Interaction coefficient -0.175 0.289 -0.769 0.418 0.549 
 TejJ89 – Marginal effect -0.112 0.139 -0.397 0.172  
 TejJ114 – Marginal 
effect -0.204 0.140 -0.491 0.083  
Hnrnpa2b1 Interaction coefficient -0.083 0.179 -0.452 0.285 0.646 
 TejJ89 – Marginal effect 0.153 0.086 -0.024 0.330  
 TejJ114 – Marginal 
effect 0.198 0.087 0.020 0.377  
Hnrnpd Interaction coefficient -0.026 0.211 -0.460 0.409 0.904 
 TejJ89 – Marginal effect 0.048 0.101 -0.160 0.257  
 TejJ114 – Marginal 
effect 0.012 0.102 -0.199 0.222  
Hnrnph3 Interaction coefficient -0.055 0.170 -0.406 0.295 0.748 
 TejJ89 – Marginal effect 0.087 0.082 -0.081 0.255  
 TejJ114 – Marginal 
effect 0.175 0.082 0.005 0.344  
Hnrnpk Interaction coefficient -0.012 0.230 -0.485 0.462 0.960 
 TejJ89 – Marginal effect -0.278 0.111 -0.505 -0.051  
 TejJ114 – Marginal 
effect -0.394 0.112 -0.624 -0.165  
Hnrnpm Interaction coefficient 0.019 0.212 -0.418 0.455 0.930 
 TejJ89 – Marginal effect -0.085 0.102 -0.294 0.125  
 TejJ114 – Marginal 
effect 0.189 0.103 -0.022 0.400  
Hnrnpul2 Interaction coefficient -0.081 0.155 -0.400 0.238 0.607 
 TejJ89 – Marginal effect 0.080 0.074 -0.073 0.233  
 TejJ114 – Marginal 
effect 0.107 0.075 -0.048 0.261  
Pnisr Interaction coefficient -0.002 0.257 -0.530 0.526 0.994 
 TejJ89 – Marginal effect 0.075 0.123 -0.178 0.329  
 TejJ114 – Marginal 
effect 0.192 0.124 -0.064 0.448  
Srsf1 Interaction coefficient 0.493 0.368 -0.265 1.251 0.193 
 TejJ89 – Marginal effect 0.287 0.174 -0.072 0.646  
 TejJ114 – Marginal 
effect 0.110 0.175 -0.252 0.471  
Srsf2 Interaction coefficient -0.491 0.206 -0.914 -0.067 0.025 
 TejJ89 – Marginal effect -0.254 0.099 -0.457 -0.051  
 TejJ114 – Marginal 
effect 0.305 0.100 0.100 0.510  
Srsf3 Interaction coefficient -0.061 0.218 -0.509 0.387 0.782 
 TejJ89 – Marginal effect -0.548 0.105 -0.763 -0.333  
 TejJ114 – Marginal 
effect -0.335 0.106 -0.552 -0.118  
Srsf6 Interaction coefficient 0.249 0.320 -0.409 0.907 0.444 
 TejJ89 – Marginal effect -0.913 0.154 -1.228 -0.597  
 TejJ114 – Marginal 
effect -0.850 0.155 -1.169 -0.532  
Tra2b Interaction coefficient 0.189 0.152 -0.123 0.502 0.224 
 TejJ89 – Marginal effect -0.049 0.073 -0.199 0.102  
 TejJ114 – Marginal 
effect -0.038 0.074 -0.189 0.114  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient 0.134 0.170 -0.215 0.482 0.439 
 TejJ89 – Marginal effect -0.276 0.081 -0.444 -0.109  
 TejJ114 – Marginal 
effect -0.474 0.082 -0.643 -0.305  
Sf3b1 Interaction coefficient -0.012 0.260 -0.546 0.522 0.964 
 TejJ89 – Marginal effect 0.485 0.125 0.229 0.741  
 TejJ114 – Marginal 
effect 0.212 0.126 -0.046 0.471  
Supplementary Table S6: Continued. 11 
Brain – Long-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient -1.057 0.408 -1.902 -0.213 0.016 
 TejJ89 – Marginal effect -0.941 0.212 -1.379 -0.503  
 TejJ114 – Marginal 
effect 0.134 0.197 -0.273 0.541  
Hnrnpa1 Interaction coefficient 1.652 0.479 0.659 2.644 0.002 
 TejJ89 – Marginal effect 1.478 0.296 0.865 2.091  
 TejJ114 – Marginal 
effect -0.208 0.208 -0.639 0.223  
Hnrnpa2b1 Interaction coefficient 0.896 0.258 0.365 1.426 0.002 
 TejJ89 – Marginal effect 0.507 0.130 0.239 0.775  
 TejJ114 – Marginal 
effect -0.408 0.120 -0.655 -0.161  
Hnrnpd Interaction coefficient 0.717 0.270 0.161 1.273 0.014 
 TejJ89 – Marginal effect 0.385 0.136 0.104 0.666  
 TejJ114 – Marginal 
effect -0.370 0.126 -0.629 -0.112  
Hnrnph3 Interaction coefficient -1.241 0.296 -1.855 -0.627 <0.001 
 TejJ89 – Marginal effect -1.536 0.183 -1.915 -1.156  
 TejJ114 – Marginal 
effect -0.272 0.129 -0.539 -0.005  
Hnrnpk Interaction coefficient 1.632 0.421 0.760 2.504 0.001 
 TejJ89 – Marginal effect 1.515 0.232 1.035 1.995  
 TejJ114 – Marginal 
effect -0.063 0.180 -0.436 0.309  
Hnrnpm Interaction coefficient -0.164 0.326 -0.834 0.507 0.620 
 TejJ89 – Marginal effect -0.175 0.165 -0.514 0.164  
 TejJ114 – Marginal 
effect -0.042 0.152 -0.354 0.271  
Hnrnpul2 Interaction coefficient 0.376 0.210 -0.055 0.808 0.084 
 TejJ89 – Marginal effect 0.096 0.106 -0.122 0.314  
 TejJ114 – Marginal 
effect -0.239 0.098 -0.440 -0.038  
Pnisr Interaction coefficient 0.026 0.318 -0.629 0.681 0.936 
 TejJ89 – Marginal effect 0.040 0.161 -0.291 0.371  
 TejJ114 – Marginal 
effect -0.048 0.148 -0.353 0.257  
Srsf1 Interaction coefficient -0.876 0.366 -1.629 -0.123 0.024 
 TejJ89 – Marginal effect -0.776 0.185 -1.157 -0.396  
 TejJ114 – Marginal 
effect 0.136 0.170 -0.214 0.487  
Srsf2 Interaction coefficient -0.845 0.433 -1.738 0.049 0.063 
 TejJ89 – Marginal effect -0.504 0.237 -0.993 -0.014  
 TejJ114 – Marginal 
effect 0.247 0.198 -0.161 0.655  
Srsf3 Interaction coefficient -1.204 0.449 -2.135 -0.274 0.014 
 TejJ89 – Marginal effect -0.976 0.272 -1.539 -0.412  
 TejJ114 – Marginal 
effect 0.224 0.184 -0.158 0.606  
Srsf6 Interaction coefficient -1.052 0.367 -1.807 -0.296 0.008 
 TejJ89 – Marginal effect -0.795 0.185 -1.176 -0.413  
 TejJ114 – Marginal 
effect 0.408 0.171 0.056 0.760  
Tra2b Interaction coefficient -0.064 0.239 -0.555 0.428 0.792 
 TejJ89 – Marginal effect 0.163 0.121 -0.086 0.411  
 TejJ114 – Marginal 
effect 0.236 0.111 0.007 0.465  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient -0.481 0.274 -1.047 0.085 0.092 
 TejJ89 – Marginal effect -0.603 0.150 -0.914 -0.293  
 TejJ114 – Marginal 
effect 0.024 0.125 -0.235 0.282  
Sf3b1 Interaction coefficient 0.665 0.422 -0.206 1.536 0.128 
 TejJ89 – Marginal effect 0.658 0.224 1.120 0.000  
 TejJ114 – Marginal 
effect -0.013 0.193 -0.412 0.386  
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Supplementary Table S6: Continued. 14 
Heart – Short-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient -0.407 0.242 -0.904 0.090 0.104 
 TejJ89 – Marginal effect -0.310 0.121 -0.560 -0.061  
 TejJ114 – Marginal 
effect 0.023 0.125 -0.233 0.279  
Hnrnpa1 Interaction coefficient -0.197 0.221 -0.651 0.258 0.383 
 TejJ89 – Marginal effect 0.242 0.111 0.015 0.470  
 TejJ114 – Marginal 
effect 0.284 0.114 0.050 0.518  
Hnrnpa2b1 Interaction coefficient 0.280 0.144 -0.016 0.575 0.063 
 TejJ89 – Marginal effect -0.019 0.071 -0.165 0.126  
 TejJ114 – Marginal 
effect -0.281 0.078 -0.440 -0.121  
Hnrnpd Interaction coefficient 0.291 0.151 -0.018 0.600 0.064 
 TejJ89 – Marginal effect -0.017 0.075 -0.172 0.138  
 TejJ114 – Marginal 
effect -0.371 0.077 -0.530 -0.212  
Hnrnph3 Interaction coefficient -0.148 0.127 -0.410 0.113 0.254 
 TejJ89 – Marginal effect -0.153 0.064 -0.284 -0.022  
 TejJ114 – Marginal 
effect 0.023 0.066 -0.111 0.158  
Hnrnpk Interaction coefficient 0.277 0.247 -0.230 0.785 0.272 
 TejJ89 – Marginal effect 0.231 0.124 -0.023 0.486  
 TejJ114 – Marginal 
effect 0.068 0.127 -0.194 0.329  
Hnrnpm Interaction coefficient -0.750 0.339 -1.446 -0.054 0.036 
 TejJ89 – Marginal effect -0.176 0.170 -0.525 0.173  
 TejJ114 – Marginal 
effect 0.603 0.175 0.244 0.961  
Hnrnpul2 Interaction coefficient 0.059 0.196 -0.344 0.462 0.767 
 TejJ89 – Marginal effect -0.140 0.098 -0.342 0.063  
 TejJ114 – Marginal 
effect -0.205 0.101 -0.412 0.003  
Pnisr Interaction coefficient -0.441 0.205 -0.864 -0.019 0.041 
 TejJ89 – Marginal effect -0.417 0.102 -0.626 -0.208  
 TejJ114 – Marginal 
effect 0.026 0.113 -0.206 0.259  
Srsf1 Interaction coefficient -0.338 0.294 -0.942 0.267 0.262 
 TejJ89 – Marginal effect -0.270 0.148 -0.573 0.033  
 TejJ114 – Marginal 
effect 0.064 0.152 -0.247 0.375  
Srsf2 Interaction coefficient -0.275 0.233 -0.753 0.203 0.249 
 TejJ89 – Marginal effect 0.183 0.117 -0.056 0.423  
 TejJ114 – Marginal 
effect 0.446 0.120 0.199 0.692  
Srsf3 Interaction coefficient -0.219 0.238 -0.708 0.270 0.366 
 TejJ89 – Marginal effect -0.113 0.120 -0.358 0.133  
 TejJ114 – Marginal 
effect 0.202 0.123 -0.050 0.454  
Srsf6 Interaction coefficient 0.584 0.248 0.074 1.093 0.026 
 TejJ89 – Marginal effect -0.131 0.125 -0.386 0.125  
 TejJ114 – Marginal 
effect -0.576 0.128 -0.838 -0.314  
Tra2b Interaction coefficient 0.138 0.189 -0.250 0.525 0.472 
 TejJ89 – Marginal effect 0.198 0.095 0.004 0.392  
 TejJ114 – Marginal 
effect 0.205 0.097 0.006 0.404  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient 0.335 0.203 -0.082 0.751 0.111 
 TejJ89 – Marginal effect -0.174 0.102 -0.383 0.035  
 TejJ114 – Marginal 
effect -0.466 0.105 -0.681 -0.252  
Sf3b1 Interaction coefficient 0.604 0.351 -0.117 1.324 0.097 
 TejJ89 – Marginal effect 0.367 0.176 0.006 0.729  
 TejJ114 – Marginal 
effect -0.354 0.181 -0.725 0.017  
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Supplementary Table S6: Continued. 17 
Heart – Long-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient 0.368 0.199 -0.043 0.778 0.077 
 TejJ89 – Marginal effect -0.025 0.096 -0.222 0.172  
 TejJ114 – Marginal 
effect -0.557 0.096 -0.754 -0.360  
Hnrnpa1 Interaction coefficient 0.016 0.221 -0.437 0.470 0.941 
 TejJ89 – Marginal effect -0.395 0.108 -0.617 -0.172  
 TejJ114 – Marginal 
effect -0.172 0.108 -0.394 0.051  
Hnrnpa2b1 Interaction coefficient 0.019 0.191 -0.374 0.412 0.922 
 TejJ89 – Marginal effect 0.238 0.094 0.045 0.431  
 TejJ114 – Marginal 
effect 0.258 0.094 0.065 0.451  
Hnrnpd Interaction coefficient 0.180 0.192 -0.215 0.574 0.358 
 TejJ89 – Marginal effect 0.109 0.094 -0.084 0.303  
 TejJ114 – Marginal 
effect 0.019 0.094 -0.175 0.212  
Hnrnph3 Interaction coefficient -0.008 0.193 -0.406 0.390 0.968 
 TejJ89 – Marginal effect -0.052 0.095 -0.247 0.143  
 TejJ114 – Marginal 
effect -0.036 0.095 -0.231 0.159  
Hnrnpk Interaction coefficient -0.247 0.235 -0.730 0.236 0.303 
 TejJ89 – Marginal effect 0.212 0.115 -0.025 0.450  
 TejJ114 – Marginal 
effect 0.284 0.115 0.047 0.521  
Hnrnpm Interaction coefficient 0.109 0.276 -0.458 0.675 0.696 
 TejJ89 – Marginal effect -0.068 0.135 -0.346 0.210  
 TejJ114 – Marginal 
effect -0.235 0.135 -0.513 0.043  
Hnrnpul2 Interaction coefficient -0.547 0.236 -1.033 -0.062 0.029 
 TejJ89 – Marginal effect -0.342 0.116 -0.581 -0.104  
 TejJ114 – Marginal 
effect 0.261 0.116 0.023 0.499  
Pnisr Interaction coefficient -0.228 0.207 -0.652 0.197 0.280 
 TejJ89 – Marginal effect -0.217 0.101 -0.426 -0.009  
 TejJ114 – Marginal 
effect 0.051 0.101 -0.157 0.259  
Srsf1 Interaction coefficient 0.079 0.281 -0.499 0.657 0.780 
 TejJ89 – Marginal effect 0.034 0.138 -0.250 0.318  
 TejJ114 – Marginal 
effect -0.112 0.138 -0.396 0.171  
Srsf2 Interaction coefficient 0.051 0.196 -0.351 0.453 0.796 
 TejJ89 – Marginal effect 0.136 0.096 -0.062 0.333  
 TejJ114 – Marginal 
effect 0.070 0.096 -0.127 0.267  
Srsf3 Interaction coefficient -0.014 0.166 -0.357 0.329 0.934 
 TejJ89 – Marginal effect 0.069 0.080 -0.096 0.233  
 TejJ114 – Marginal 
effect -0.314 0.080 -0.478 -0.149  
Srsf6 Interaction coefficient 0.303 0.253 -0.217 0.824 0.242 
 TejJ89 – Marginal effect 0.710 0.124 0.454 0.965  
 TejJ114 – Marginal 
effect 0.266 0.124 0.011 0.521  
Tra2b Interaction coefficient -0.089 0.257 -0.618 0.441 0.733 
 TejJ89 – Marginal effect 0.352 0.126 0.092 0.612  
 TejJ114 – Marginal 
effect 0.307 0.126 0.047 0.566  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient 0.411 0.225 -0.052 0.874 0.079 
 TejJ89 – Marginal effect 0.073 0.111 -0.154 0.301  
 TejJ114 – Marginal 
effect -0.307 0.110 -0.534 -0.080  
Sf3b1 Interaction coefficient 0.109 0.298 -0.504 0.723 0.717 
 TejJ89 – Marginal effect -0.290 0.146 -0.591 0.011  
 TejJ114 – Marginal 
effect -0.257 0.146 -0.558 0.044  
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Supplementary Table S6: Continued. 20 
Kidney – Short-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient 0.051 0.280 -0.523 0.625 0.856 
 TejJ89 – Marginal effect 0.196 0.142 -0.094 0.486  
 TejJ114 – Marginal 
effect 0.171 0.134 -0.104 0.445  
Hnrnpa1 Interaction coefficient -0.310 0.132 -0.580 -0.039 0.027 
 TejJ89 – Marginal effect -0.496 0.067 -0.633 -0.359  
 TejJ114 – Marginal 
effect -0.081 0.063 -0.210 0.049  
Hnrnpa2b1 Interaction coefficient -0.054 0.153 -0.368 0.260 0.725 
 TejJ89 – Marginal effect -0.172 0.077 -0.331 -0.013  
 TejJ114 – Marginal 
effect -0.112 0.073 -0.262 0.038  
Hnrnpd Interaction coefficient 0.152 0.131 -0.117 0.422 0.255 
 TejJ89 – Marginal effect 0.036 0.069 -0.107 0.179  
 TejJ114 – Marginal 
effect -0.082 0.062 -0.209 0.045  
Hnrnph3 Interaction coefficient 0.033 0.136 -0.246 0.312 0.812 
 TejJ89 – Marginal effect -0.086 0.069 -0.227 0.055  
 TejJ114 – Marginal 
effect -0.133 0.065 -0.266 0.000  
Hnrnpk Interaction coefficient -0.226 0.146 -0.526 0.074 0.133 
 TejJ89 – Marginal effect -0.004 0.074 -0.155 0.148  
 TejJ114 – Marginal 
effect 0.171 0.070 0.028 0.314  
Hnrnpm Interaction coefficient 0.192 0.178 -0.173 0.558 0.290 
 TejJ89 – Marginal effect 0.336 0.090 0.151 0.521  
 TejJ114 – Marginal 
effect 0.136 0.085 -0.039 0.311  
Hnrnpul2 Interaction coefficient 0.088 0.177 -0.275 0.452 0.622 
 TejJ89 – Marginal effect -0.254 0.090 -0.438 -0.070  
 TejJ114 – Marginal 
effect -0.349 0.085 -0.523 -0.175  
Pnisr Interaction coefficient -0.029 0.183 -0.405 0.346 0.873 
 TejJ89 – Marginal effect -0.284 0.093 -0.474 -0.094  
 TejJ114 – Marginal 
effect -0.251 0.088 -0.431 -0.072  
Srsf1 Interaction coefficient -0.159 0.105 -0.375 0.057 0.143 
 TejJ89 – Marginal effect 0.127 0.053 0.018 0.237  
 TejJ114 – Marginal 
effect 0.280 0.050 0.177 0.383  
Srsf2 Interaction coefficient -0.077 0.178 -0.443 0.289 0.668 
 TejJ89 – Marginal effect 0.079 0.090 -0.106 0.264  
 TejJ114 – Marginal 
effect 0.169 0.085 -0.006 0.344  
Srsf3 Interaction coefficient -0.363 0.204 -0.781 0.055 0.086 
 TejJ89 – Marginal effect 0.119 0.103 -0.092 0.331  
 TejJ114 – Marginal 
effect 0.445 0.097 0.245 0.645  
Srsf6 Interaction coefficient 0.238 0.225 -0.223 0.699 0.298 
 TejJ89 – Marginal effect 0.744 0.114 0.511 0.978  
 TejJ114 – Marginal 
effect 0.444 0.107 0.224 0.664  
Tra2b Interaction coefficient -0.145 0.156 -0.466 0.177 0.364 
 TejJ89 – Marginal effect 0.382 0.078 0.222 0.542  
 TejJ114 – Marginal 
effect 0.461 0.078 0.301 0.621  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient 0.554 0.153 0.241 0.867 0.001 
 TejJ89 – Marginal effect 0.091 0.077 -0.068 0.249  
 TejJ114 – Marginal 
effect -0.488 0.073 -0.637 -0.338  
Sf3b1 Interaction coefficient 0.219 0.222 -0.236 0.674 0.332 
 TejJ89 – Marginal effect -0.346 0.112 -0.576 -0.115  
 TejJ114 – Marginal 
effect -0.526 0.106 -0.744 -0.309  
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Supplementary Table S6: Continued. 23 
Kidney – Long-term DR 
   Coefficient SE 95% CI 
lower 
95% CI 
upper 
p-
value 
S
p
li
c
in
g
 F
a
c
to
rs
 
Hnrnpa0 Interaction coefficient -0.067 0.211 -0.501 0.368 0.755 
 TejJ89 – Marginal effect -0.016 0.108 -0.237 0.206  
 TejJ114 – Marginal 
effect 0.306 0.095 0.110 0.503  
Hnrnpa1 Interaction coefficient 0.014 0.245 -0.490 0.519 0.954 
 TejJ89 – Marginal effect -0.486 0.125 -0.744 -0.229  
 TejJ114 – Marginal 
effect -0.164 0.111 -0.392 0.064  
Hnrnpa2b1 Interaction coefficient 0.184 0.239 -0.309 0.677 0.449 
 TejJ89 – Marginal effect -0.277 0.120 -0.524 -0.030  
 TejJ114 – Marginal 
effect -0.300 0.112 -0.531 -0.069  
Hnrnpd Interaction coefficient -0.045 0.170 -0.396 0.305 0.792 
 TejJ89 – Marginal effect 0.064 0.087 -0.114 0.243  
 TejJ114 – Marginal 
effect 0.105 0.077 -0.053 0.264  
Hnrnph3 Interaction coefficient -0.336 0.284 -0.924 0.252 0.250 
 TejJ89 – Marginal effect -0.509 0.139 -0.796 -0.222  
 TejJ114 – Marginal 
effect -0.414 0.149 -0.722 -0.107  
Hnrnpk Interaction coefficient -0.146 0.218 -0.595 0.303 0.508 
 TejJ89 – Marginal effect 0.162 0.111 -0.067 0.391  
 TejJ114 – Marginal 
effect -0.050 0.099 -0.253 0.153  
Hnrnpm Interaction coefficient 0.106 0.280 -0.472 0.683 0.709 
 TejJ89 – Marginal effect 0.202 0.143 -0.092 0.497  
 TejJ114 – Marginal 
effect 0.009 0.127 -0.251 0.270  
Hnrnpul2 Interaction coefficient -0.385 0.216 -0.831 0.061 0.087 
 TejJ89 – Marginal effect 0.074 0.106 -0.145 0.294  
 TejJ114 – Marginal 
effect 0.259 0.093 0.067 0.452  
Pnisr Interaction coefficient 0.384 0.257 -0.145 0.913 0.147 
 TejJ89 – Marginal effect 0.436 0.131 0.167 0.706  
 TejJ114 – Marginal 
effect 0.155 0.116 -0.084 0.394  
Srsf1 Interaction coefficient -0.212 0.107 -0.432 0.008 0.058 
 TejJ89 – Marginal effect -0.127 0.054 -0.239 -0.015  
 TejJ114 – Marginal 
effect -0.012 0.048 -0.111 0.088  
Srsf2 Interaction coefficient 0.365 0.296 -0.245 0.975 0.229 
 TejJ89 – Marginal effect 0.218 0.151 -0.093 0.529  
 TejJ114 – Marginal 
effect -0.076 0.134 -0.351 0.200  
Srsf3 Interaction coefficient -0.307 0.269 -0.862 0.248 0.265 
 TejJ89 – Marginal effect -0.062 0.137 -0.345 0.221  
 TejJ114 – Marginal 
effect -0.068 0.122 -0.319 0.182  
Srsf6 Interaction coefficient -0.237 0.251 -0.754 0.279 0.353 
 TejJ89 – Marginal effect 0.180 0.128 -0.083 0.444  
 TejJ114 – Marginal 
effect 0.093 0.113 -0.140 0.327  
Tra2b Interaction coefficient -0.269 0.329 -0.946 0.408 0.421 
 TejJ89 – Marginal effect -0.072 0.168 -0.417 0.273  
 TejJ114 – Marginal 
effect -0.173 0.149 -0.479 0.133  
C
o
re
 
S
p
li
c
e
o
s
o
m
e
 
Sf1 Interaction coefficient -0.049 0.180 -0.421 0.322 0.787 
 TejJ89 – Marginal effect 0.154 0.092 -0.036 0.343  
 TejJ114 – Marginal 
effect 0.176 0.082 0.008 0.344  
Sf3b1 Interaction coefficient 0.114 0.250 -0.400 0.629 0.651 
 TejJ89 – Marginal effect 0.170 0.127 -0.092 0.432  
 TejJ114 – Marginal 
effect 0.281 0.113 0.048 0.513  
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